| Followers | 0 |
| Posts | 48 |
| Boards Moderated | 0 |
| Alias Born | 06/06/2022 |
Wednesday, March 22, 2023 11:23:53 AM
Really? So fda said we want these endpoints and mf said nope we are good with the old ones? That doesn’t sound much like a back and forth to agree on endpoints. That is the fda saying we will accept these endpoints and mf, in all his brilliance, saying no I feel like screwing everyone and wasting the past year so I will stick with the old ones. I’m sure you will have an excuse for that as well. Just make sure you buy all the shares in the next dilution to fund the rest of the trial that has no patients. It takes some sort of idiot not to unblind a trial that you know you can’t finish. At this point he is just dragging this thing out. Unblind and sell based on the pcr data and maybe they can salvage a couple hundred mill.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
